FDA Panel Unanimously Backs Moderna's Next-Generation mRNA Flu Vaccine

Moderna's mRNA flu vaccine has secured unanimous FDA advisory support, marking a significant expansion of mRNA technology beyond COVID-19 into preventive care for seasonal diseases. With 27% higher efficacy against conventional flu shots, this approval demonstrates the platform's versatility and potential for rapid vaccine development. The decision signals scientific consensus on mRNA's viability as a mainstream vaccine approach and strengthens preparedness for future pandemic threats.